DGIdb - EPTIFIBATIDE Drug Record

EPTIFIBATIDE chembl:CHEMBL1174 Approved

Alternate Names:

EPTIFIBATIDE
INTEGRILIN
INTEGRELIN®
N(6)-AMIDINO-N(2)-(3-MERCAPTOPROPIONYL)-L-LYSYLGLYCYL-L-ALPHA-ASPARTYL-L-TRYPTOPHYL-L-PROLYL-L-CYSTEINAMIDE, CYCLIC(1-6)-DISULFIDE
C68-22
S(1),S(6)-CYCLO[N(6)-CARBAMIMIDOYL-N(2)-(3-SULFANYLPROPANOYL)-L-LYSYLGLYCYL-L-ALPHA-ASPARTYL-L-TRYPTOPHYL-L-PROLYL-L-CYSTEINAMIDE]
chemidplus:188627-80-7
chembl:CHEMBL1174
rxcui:75635
pubchem.compound:448812
drugbank:00063

Drug Info:

Drug Class	platelet aggregation inhibitors
Year of Approval	1998
FDA Approval	approved
Drug Class	peptide
Drug Indications	antiplatelet agent

(2 More Sources)

Publications:

Sangkuhl K et al., 2011, Platelet aggregation pathway., Pharmacogenet Genomics
Fischer et al., 2005, Synergistic platelet integrin signaling and factor XII activation in poly-N-acetyl glucosamine fiber-mediated hemostasis., Biomaterials
Berman et al., 2000, The Protein Data Bank., Nucleic Acids Res.
Schrör et al., 2003, Comparative pharmacology of GP IIb/IIIa antagonists., J. Thromb. Thrombolysis
Auer et al., 2003, [Platelet glycoprotein IIb/IIIa inhibitors in coronary artery disease]., Herz
Weber et al., 2002, No evidence for an influence of the human platelet antigen-1 polymorphism on the antiplatelet effects of glycoprotein IIb/IIIa inhibitors., Pharmacogenetics
Amoroso et al., 2001, Eptifibatide and abciximab exhibit equivalent antiplatelet efficacy in an experimental model of stenting in both healthy volunteers and patients with coronary artery disease., J. Cardiovasc. Pharmacol.
Schwarz et al., 2004, Reversibility versus persistence of GPIIb/IIIa blocker-induced conformational change of GPIIb/IIIa (alphaIIbbeta3, CD41/CD61)., J. Pharmacol. Exp. Ther.

EPTIFIBATIDE ITGB3

Interaction Score: 10.6

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name eptifibatide,Integrilin

Novel drug target Established target

Mechanism of Interaction Integrin alpha-IIb/beta-3 inhibitor

PMIDs:
20938371 15860200 10592235 14618072 12928738 12360110 11588534 14617694

Sources:
TdgClinicalTrial ChemblInteractions TEND PharmGKB
EPTIFIBATIDE ITGA2B

Interaction Score: 5.5

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name eptifibatide,Integrilin

Novel drug target Established target

Mechanism of Interaction Integrin alpha-IIb/beta-3 inhibitor

PMIDs:
20938371

Sources:
TdgClinicalTrial ChemblInteractions PharmGKB
EPTIFIBATIDE FGG

Interaction Score: 4.95

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20938371

Sources:
PharmGKB
EPTIFIBATIDE FGB

Interaction Score: 3.53

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20938371

Sources:
PharmGKB
EPTIFIBATIDE FGA

Interaction Score: 3.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20938371

Sources:
PharmGKB

TEND: EPTIFIBATIDE
- Version: 01-August-2011
Alternate Names:

EPTIFIBATIDE Primary Drug Name

Drug Info:

Year of Approval 1998

Drug Class platelet aggregation inhibitors

Publications:
TdgClinicalTrial: EPTIFIBATIDE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antiplatelet agent

Drug Class peptide

FDA Approval approved

Publications:
PharmGKB: eptifibatide
- Version: 18-August-2020
Alternate Names:

Drug Info:

Publications:

Sangkuhl K et al., 2011, Platelet aggregation pathway., Pharmacogenet Genomics
TTD: Eptifibatide
- Version: 2020.06.01
Alternate Names:

D09ZIO TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL1174
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL1174
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:

Trial Name	eptifibatide,Integrilin
Novel drug target	Established target
Mechanism of Interaction	Integrin alpha-IIb/beta-3 inhibitor

EPTIFIBATIDE Drug Record

EPTIFIBATIDE chembl:CHEMBL1174 Approved

Alternate Names:

Drug Info:

Publications:

EPTIFIBATIDE ITGB3

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name eptifibatide,Integrilin Novel drug target Established target Mechanism of Interaction Integrin alpha-IIb/beta-3 inhibitor

PMIDs: 20938371 15860200 10592235 14618072 12928738 12360110 11588534 14617694

Sources: TdgClinicalTrial ChemblInteractions TEND PharmGKB

EPTIFIBATIDE ITGA2B

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name eptifibatide,Integrilin Novel drug target Established target Mechanism of Interaction Integrin alpha-IIb/beta-3 inhibitor

PMIDs: 20938371

Sources: TdgClinicalTrial ChemblInteractions PharmGKB

EPTIFIBATIDE FGG

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 20938371

Sources: PharmGKB

EPTIFIBATIDE FGB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 20938371

Sources: PharmGKB

EPTIFIBATIDE FGA

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 20938371

Sources: PharmGKB

TEND: EPTIFIBATIDE

Alternate Names: EPTIFIBATIDE Primary Drug Name

Drug Info: Year of Approval 1998 Drug Class platelet aggregation inhibitors

Publications:

TdgClinicalTrial: EPTIFIBATIDE

Alternate Names:

Drug Info: Drug Indications antiplatelet agent Drug Class peptide FDA Approval approved

Publications:

PharmGKB: eptifibatide

Alternate Names:

Drug Info:

Publications: Sangkuhl K et al., 2011, Platelet aggregation pathway., Pharmacogenet Genomics

TTD: Eptifibatide

Alternate Names: D09ZIO TTD Drug ID

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL1174

Alternate Names:

Drug Info:

Publications:

ChemblInteractions: CHEMBL1174

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name eptifibatide,Integrilin

Novel drug target Established target

Mechanism of Interaction Integrin alpha-IIb/beta-3 inhibitor

PMIDs:
20938371 15860200 10592235 14618072 12928738 12360110 11588534 14617694

Sources:
TdgClinicalTrial ChemblInteractions TEND PharmGKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name eptifibatide,Integrilin

Novel drug target Established target

Mechanism of Interaction Integrin alpha-IIb/beta-3 inhibitor

PMIDs:
20938371

Sources:
TdgClinicalTrial ChemblInteractions PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
20938371

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
20938371

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
20938371

Sources:
PharmGKB

Alternate Names:

EPTIFIBATIDE Primary Drug Name

Drug Info:

Year of Approval 1998

Drug Class platelet aggregation inhibitors

Drug Info:

Drug Indications antiplatelet agent

Drug Class peptide

FDA Approval approved

Publications:

Sangkuhl K et al., 2011, Platelet aggregation pathway., Pharmacogenet Genomics

Alternate Names:

D09ZIO TTD Drug ID